(CB1MDX) Lyxor 1 MDAX (DR) I CHF - Ratings and Ratios
Exchange: SW •
Country: Switzerland •
Currency: CHF •
Type: Etf •
ISIN: DE000ETF9074
Stocks, Equities, Germany, Small, Cap, Shares, Investments
Description: CB1MDX Lyxor 1 MDAX (DR) I CHF
URL: http://www.amundi.com Index: MSCI Germany Small Cap NR EUR
Additional Sources for CB1MDX ETF
CB1MDX ETF Overview
| Market Cap in USD | 121m |
| Category | Germany Small/Mid-Cap Equity |
| TER | 0.30% |
| IPO / Inception | 2015-10-30 |
CB1MDX ETF Ratings
| Growth Rating | -21.8 |
| Fundamental | - |
| Dividend Rating | 57.9 |
| Rel. Strength | -1.18 |
| Analysts | - |
| Fair Price Momentum | 135.50 CHF |
| Fair Price DCF | - |
CB1MDX Dividends
| Dividend Yield 12m | 1.68% |
| Yield on Cost 5y | 1.56% |
| Annual Growth 5y | 10.46% |
| Payout Consistency | 90.7% |
| Payout Ratio | % |
CB1MDX Growth Ratios
| Growth Correlation 3m | 58.4% |
| Growth Correlation 12m | -45.8% |
| Growth Correlation 5y | -50.4% |
| CAGR 5y | -5.93% |
| CAGR/Max DD 5y | -0.13 |
| Sharpe Ratio 12m | 0.33 |
| Alpha | -26.13 |
| Beta | 0.412 |
| Volatility | 21.62% |
| Current Volume | 0.2k |
| Average Volume 20d | 0k |
| Stop Loss | 134.4 (-3%) |
What is the price of CB1MDX shares?
As of July 15, 2025, the stock is trading at CHF 138.52 with a total of 245 shares traded.
Over the past week, the price has changed by +1.30%, over one month by +2.55%, over three months by +16.42% and over the past year by +13.20%.
As of July 15, 2025, the stock is trading at CHF 138.52 with a total of 245 shares traded.
Over the past week, the price has changed by +1.30%, over one month by +2.55%, over three months by +16.42% and over the past year by +13.20%.
Is Lyxor 1 MDAX (DR) I CHF a good stock to buy?
Neither. Based on ValueRay´s Analyses, Lyxor 1 MDAX (DR) I CHF is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -21.76 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CB1MDX is around 135.50 CHF . This means that CB1MDX is currently overvalued and has a potential downside of -2.18%.
Neither. Based on ValueRay´s Analyses, Lyxor 1 MDAX (DR) I CHF is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -21.76 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CB1MDX is around 135.50 CHF . This means that CB1MDX is currently overvalued and has a potential downside of -2.18%.
Is CB1MDX a buy, sell or hold?
Lyxor 1 MDAX (DR) I CHF has no consensus analysts rating.
Lyxor 1 MDAX (DR) I CHF has no consensus analysts rating.
What are the forecasts for CB1MDX share price target?
According to our own proprietary Forecast Model, CB1MDX Lyxor 1 MDAX (DR) I CHF will be worth about 149.9 in July 2026. The stock is currently trading at 138.52. This means that the stock has a potential upside of +8.2%.
According to our own proprietary Forecast Model, CB1MDX Lyxor 1 MDAX (DR) I CHF will be worth about 149.9 in July 2026. The stock is currently trading at 138.52. This means that the stock has a potential upside of +8.2%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 149.9 | 8.2% |